ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

Rhea-AI Summary

ESSA Pharma Inc. (NASDAQ: EPIX) held its Annual General Meeting of Shareholders on March 5, 2025. The company, which previously focused on developing prostate cancer therapies before discontinuing its clinical trials and development programs, announced key shareholder votes.

Shareholders approved setting the board size at seven directors and re-elected David R. Parkinson, Richard M. Glickman, Franklin M. Berger, Scott Requadt, Marella Thorell, Alex Martin, and Sandy Zweifach. Additional approvals included the re-appointment of Davidson & Company LLP as auditors and a non-binding advisory vote on executive compensation.

Positive

• All proposed board members successfully re-elected
• Shareholder approval received for all agenda items

Negative

• Clinical trials and development programs discontinued
• No active drug development pipeline

SOUTH SAN FRANCISCO, USA and VANCOUVER, Canada, March 6, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, has been focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on March 5, 2025 (the "Meeting").

At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at seven and re-elected to the board of directors, by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Franklin M. Berger, Scott Requadt, Marella Thorell, Alex Martin and Sandy Zweifach to serve in office until the next annual meeting or until their successors are duly elected or appointed. Detailed results of the voting in respect of the election of directors are as follows:

Nominee	Votes For	% Votes For	Votes Withheld	% Votes Withheld
David R. Parkinson	9,131,148	98.83 %	108,123	1.17 %
Richard M. Glickman	8,823,885	95.50 %	415,386	4.50 %
Franklin M. Berger	8,807,588	95.33 %	431,683	4.67 %
Scott Requadt	9,130,637	98.82 %	108,634	1.18 %
Marella Thorell	9,135,934	98.88 %	103,337	1.12 %
Alex Martin	9,132,226	98.84 %	107,045	1.16 %
Sandy Zweifach	9,112,900	98.63 %	126,371	1.37 %

At the Meeting, the Shareholders also approved: (i) the re-appointment of Davidson & Company LLP, Chartered Professional Accountants, as auditors of the Company; and (ii) on a non-binding advisory basis, the compensation of the Company's named executive officers.

Contact Information:

David Wood
Chief Financial Officer, ESSA Pharma Inc.
T: 778-331-0962
E: dwood@essapharma.com

About ESSA Pharma Inc.

ESSA is a pharmaceutical company that was previously focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essapharma.com.

View original content:https://www.prnewswire.com/news-releases/essa-pharma-inc-reports-results-of-annual-general-meeting-of-shareholders-302394301.html

SOURCE ESSA Pharma Inc

FAQ

What major decisions were made at EPIX's 2025 Annual General Meeting?

Shareholders approved a seven-member board, re-elected all directors, reappointed Davidson & Company LLP as auditors, and approved executive compensation on a non-binding basis.

Who are the current board members of ESSA Pharma (EPIX) following the 2025 AGM?

The board consists of David R. Parkinson, Richard M. Glickman, Franklin M. Berger, Scott Requadt, Marella Thorell, Alex Martin, and Sandy Zweifach.

What is the current status of EPIX's clinical trials and development programs?

The company has discontinued its clinical trials and development programs that were previously focused on prostate cancer therapies.

When did ESSA Pharma (EPIX) hold its 2025 Annual General Meeting?

ESSA Pharma held its Annual General Meeting on March 5, 2025.